Kardiale Nebenwirkungen von Radio- und Chemotherapie – Besonderheiten bei älteren Menschen

In dieser Arbeit sollen die kardiotoxischen Mechanismen, die besonders prädisponierenden Substanzen, die klinischen Manifestationen am Herzen, die Prävention und Therapie kardiotoxischer Effekte durch insbesondere Chemotherapeutika diskutiert werden. Ein spezielles Kapitel ist dem kardiovaskulären Risiko von Mammakarzinom-Patientinnen und möglichen Interaktionen kardialer Risikofaktoren zum Mammakarzinomrisiko sowie gemeinsamen therapeutischen Implikationen gewidmet.

In this article, we discuss the cardiotoxic mechanisms, the particularly predisposing substances, the clinical manifestations on the heart and the prevention of as well as therapy for the cardiotoxic effects of specific chemotherapeutic agents. A special section is dedicated to the cardiovascular risks of breast cancer patients and the possible interactions of cardiac risk factors with the risk for breast cancer as well as their common therapeutic implications.

Key words

radiotherapy - chemotherapy - elder patients - cardiac side effects

• Literatur

• 1 Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-3148
• 2 Gyenes G, Rutqvist LE, Liedberg A et al. Long – term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol 1998; 48: 185-190
• 3 Ewer SE, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol 2010; 28: 3901-3904
• 4 Yeh ETH, Tong AT, Lenihan DJ et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-3131
• 5 Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am J Heart J 2005; 150: 977-982
• 6 Eschenhagen Th, Force Th, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Europ J Heart Failure 2011; 13: 1-10
• 7 Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol 2009; 53: 2231-2247
• 8 Cardinale D, Colombo A, Torrisi R et al. Trastuzumab – induced cardiotoxicity. Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-3916
• 9 Lipshultz S, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94: 525-533
• 10 Ho E, Brown A, Barrett P et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010; 96: 701-707
• 11 Sawaya H, Sebag AI, Plana CJ et al. Early detection and prediction of cardiotoxicity in chemotherapy – treated patients. Am J Cardiol 2011; 107: 1375-1380
• 12 Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754
• 13 Cardinale D, Colombo A, Sandri MT et al. Prevention of high – dose chemotherapy induced cardiotoxicity in high- risk patients by angiotensin – converting enzyme inhibition. Circulation 2006; 114: 2474-2481
• 14 Jones LW, Haykowsky MJ, Swartz JJ et al. Early Breast Cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50: 1435-1441